- Home
- BIVI vs PHGE Comparison
BIVI vs PHGE Comparison
Compare BIVI & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- PHGE
- Stock Information
- Founded
- BIVI 2013
- PHGE 2015
- Country
- BIVI United States
- PHGE Israel
- Employees
- BIVI N/A
- PHGE N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- BIVI Health Care
- PHGE Health Care
- Exchange
- BIVI Nasdaq
- PHGE Nasdaq
- Market Cap
- BIVI 14.2M
- PHGE 15.5M
- IPO Year
- BIVI N/A
- PHGE N/A
- Fundamental
- Price
- BIVI $1.91
- PHGE $0.57
- Analyst Decision
- BIVI
- PHGE Strong Buy
- Analyst Count
- BIVI 0
- PHGE 1
- Target Price
- BIVI N/A
- PHGE $15.00
- AVG Volume (30 Days)
- BIVI 184.5K
- PHGE 379.7K
- Earning Date
- BIVI 11-12-2025
- PHGE 11-13-2025
- Dividend Yield
- BIVI N/A
- PHGE N/A
- EPS Growth
- BIVI N/A
- PHGE N/A
- EPS
- BIVI N/A
- PHGE N/A
- Revenue
- BIVI N/A
- PHGE N/A
- Revenue This Year
- BIVI N/A
- PHGE N/A
- Revenue Next Year
- BIVI N/A
- PHGE N/A
- P/E Ratio
- BIVI N/A
- PHGE N/A
- Revenue Growth
- BIVI N/A
- PHGE N/A
- 52 Week Low
- BIVI $1.42
- PHGE $0.34
- 52 Week High
- BIVI $75.00
- PHGE $1.16
- Technical
- Relative Strength Index (RSI)
- BIVI 46.41
- PHGE 55.95
- Support Level
- BIVI $1.81
- PHGE $0.57
- Resistance Level
- BIVI $2.07
- PHGE $0.65
- Average True Range (ATR)
- BIVI 0.13
- PHGE 0.05
- MACD
- BIVI 0.03
- PHGE 0.00
- Stochastic Oscillator
- BIVI 37.99
- PHGE 64.16
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).